Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

Core Insights - Akari Therapeutics has appointed Dr. Prafulla Gokhale to its Scientific Advisory Board, enhancing its expertise in oncology drug development as it advances its lead candidate AKTX-101 toward clinical trials [1][2][4] Company Overview - Akari Therapeutics is focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing, differentiating it from conventional ADCs that use tubulin inhibitors or DNA-damaging agents [7] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has shown significant activity in preclinical studies, indicating prolonged survival compared to traditional ADCs [7] - The company is also developing AKTX-102, which targets CEACAM5, a tumor antigen expressed across multiple solid tumors, leveraging the same PH1 payload for enhanced therapeutic effects [7] Dr. Prafulla Gokhale's Role - Dr. Gokhale brings over 20 years of experience in preclinical oncology drug discovery and development, having previously led pharmacology teams at major pharmaceutical companies [4] - His expertise in experimental therapeutics and translational oncology is expected to strengthen Akari's clinical strategies for AKTX-101, ensuring a data-driven approach as the company prepares for first-in-human studies [2][6] Mechanism of Action - The PH1 payload is designed to modulate spliceosomes, disrupting RNA splicing within cancer cells, which has been shown to induce cancer cell death while engaging both innate and adaptive immune responses [5][7] - Preclinical models indicate that AKTX-101 may work synergistically with checkpoint inhibitors, enhancing its therapeutic potential [7]